Register for the ESMO Post Show Roundtable
Highlights from the virtual conference
Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.
The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.
The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.